ONTARIO, Calif., Oct. 6, 2003 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, announced today that it will be presenting at the Third Annual Biotech In Europe Investor Forum on November 5, 2003 in Munich, Germany.
The meeting is an investment forum comprised of over 400 Venture Capitalists, Fund Managers and Institutional Investors from Europe and is sponsored by Sachs Associates and Bloomberg L.P.
"We are looking forward to our first opportunity to present LifePoint to potential European investors," stated Linda H. Masterson, CEO & President of LifePoint. "We believe that there will be a substantial interest in LifePoint by investors in Europe because of the high visibility and awareness of the drugged driver problem within the European community. Additionally, in Europe, saliva is already well-established and accepted as a viable sample for diagnostic testing, including drug testing, which is a major reason for the significant demand we expect from the European community for the LifePoint(r) IMPACT(r) Test System."
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT(r) Test System -- a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets -- law enforcement, industrial workplace and medical emergency room - are estimated to be over $1.6 billion in total opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the need to hire personnel, dependence on third parties for certain marketing efforts, FDA 510(k) clearance in U.S. medical markets, market acceptance and potential need for additional financing. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc